10-Q Filing

SOLENO THERAPEUTICS INC CIK: 1484565 Q3 2023

Filing Information

Form Type	10-Q
Accession Number	`0000950170-23-060438`
Period End Date	20230930
Filing Date	20231108
Fiscal Year	2023
Fiscal Period	Q3
XBRL Instance	slno-20230930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 75 Income Statement 68 Cash Flow Statement 54 Stockholders Equity 48

Balance Sheet 75 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	15.47M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.16M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	15.47M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$52.44M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$14.60M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.16M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.04M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.22M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$53.66M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.65M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$26.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$15.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$474.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$131.00K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$10.69M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$9.23M	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$165.00K	USD	Point-in-time
Total assets	`Assets`	$63.55M	USD	Point-in-time
Total assets	`Assets`	$26.50M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.78M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.22M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$1.50M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$1.68M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.24M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.22M	USD	Point-in-time
Common stock purchase liability	`CommonStockPurchaseLiability`	$19.94M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$155.00K	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$256.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$848.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$484.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$28.99M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.31M	USD	Point-in-time
Operating lease liabilities - noncurrent	`OperatingLeaseLiabilityNoncurrent`	$214.00K	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$10.47M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$8.84M	USD	Point-in-time
Total liabilities	`Liabilities`	$16.15M	USD	Point-in-time
Total liabilities	`Liabilities`	$40.33M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 15,467,229 and 8,159,382 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$8.00K	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 15,467,229 and 8,159,382 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$15.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$247.76M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$288.32M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-265.11M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-237.42M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$10.35M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$15.20M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$23.22M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$26.46M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$20.31M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$2.64M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$17.79M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$12.43M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$26.50M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$63.55M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$16.50M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.77M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$11.46M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$6.04M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$7.44M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$9.34M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.33M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.32M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$132.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$1.63M	USD	3 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$1.02M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-110.00K	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$10.38M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$27.47M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$6.24M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$18.79M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-6.24M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-10.38M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-27.47M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-18.79M	USD	3 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-31.00K	USD	3 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$652.00K	USD	3 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$653.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$101.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$174.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$434.00K	USD	3 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$175.00K	USD	3 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$-479.00K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-218.00K	USD	3 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$103.00K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$206.00K	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-8.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-27.69M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-10.86M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-18.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-8.36M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.13M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$16.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-18.58M	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-27.69M	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-6.13M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-10.86M	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-2.31	USD	3 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.65	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-0.95	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-2.65	USD	3 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-2.31	USD	3 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.65	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.95	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-2.65	USD	3 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	8.05M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	9.42M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	11.44M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	10.44M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	9.42M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	8.05M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	11.44M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	10.44M	shares	3 Qtrs

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-27.69M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-18.58M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.48M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.47M	USD	3 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$254.00K	USD	3 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$215.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.90M	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$4.04M	USD	3 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-31.00K	USD	3 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$652.00K	USD	3 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$653.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$132.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$1.63M	USD	3 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$1.02M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-110.00K	USD	3 Qtrs
Other non-cash reconciling items	`OtherNonCashReconcilingItems`	$-2.00K	USD	3 Qtrs
Other non-cash reconciling items	`OtherNonCashReconcilingItems`	$-1.00K	USD	3 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-337.00K	USD	3 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$177.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-930.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.34M	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$554.00K	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-177.00K	USD	3 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$15.00K	USD	3 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$-594.00K	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-218.00K	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-242.00K	USD	3 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$266.00K	USD	3 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$348.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-18.63M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-15.64M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-7.00K	USD	3 Qtrs
Proceeds from sale of common stock and common stock warrants, net of issuance costs	`ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts`	$17.07M	USD	3 Qtrs
Proceeds from sale of common stock and pre-funded warrants, net of costs	`ProceedsFromSaleOfCommonStockAndPreFundedWarrantsNetOfCosts`	$14.11M	USD	3 Qtrs
Proceeds from exercise of common stock warrants, net of costs	`ProceedsFromWarrantExercises`	$19.45M	USD	3 Qtrs
Proceeds received prior to for issuance of common stock and pre-funded warrants	`ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants`	$19.93M	USD	3 Qtrs
Proceeds from stock option exercises	`ProceedsFromStockOptionsExercised`	$10.00K	USD	3 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$56.46M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.09M	USD	3 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$37.84M	USD	3 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.55M	USD	3 Qtrs
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.75M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.60M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$52.44M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.75M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.60M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$52.44M	USD	Point-in-time
Operating lease right-of-use assets obtained in exchange for operating lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$597.00K	USD	3 Qtrs
Unpaid financing costs included in accounts payable and accrued liabilities	`UnpaidCostsForIssuingCommonStockAndPreFundedWarrants`	$199.00K	USD	3 Qtrs

Stockholders Equity 48 line items

Line Item	Tag	Value	Unit	Period
Less transaction costs	`PaymentsOfStockIssuanceCosts`	$1.03M	USD	1 Quarter
Balances at beginning	`StockholdersEquity`	$10.35M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$15.20M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$23.22M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$2.64M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$12.43M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$571.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$464.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$495.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$2.20M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.20M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$683.00K	USD	1 Quarter
Issuance of common stock warrants, net of issuance costs	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$9.97M	USD	1 Quarter
Issuance of restricted stock units under equity incentive plan	`IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan`	$180.00K	USD	1 Quarter
Issuance of restricted stock units under equity incentive plan	`IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan`	$136.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$342.00K	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$7.10M	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$13.77M	USD	1 Quarter
Exercise of common stock warrants	`ClassOfWarrantOrRightExercisedValue`	$19.45M	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$10.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$16.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-27.69M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-10.86M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-18.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-8.36M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.13M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Balances at ending	`StockholdersEquity`	$10.35M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$15.20M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$23.22M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$2.64M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$12.43M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.